HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality: ? Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market ? Prostate cancer targeting US$350m pa market A biomarker is a specific biochemical in the body that measures disease or the effects of treatment. HealthLinx has commenced the second larger study for OvPlex aiming to prove a diagnostic accuracy of over 97 per cent for early stage ovarian cancer. This larger study is based on 1150 new samples using existing OvPlex biomarkers and including two novel biomarkers AGR2 and HTX010. The study will be a robust comparison of sensitivity and specificity especially for early stage diagnosis in symptomatic women. The objective is to cement the position of OvPlex? as the world?s most accurate and efficient ovarian cancer diagnostic.
HTX Price at posting:
6.2¢ Sentiment: None Disclosure: Not Held
